IKT
NASDAQ
$2.23
Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6 (+169.06%)
Market Cap
$272M
FCF 5Y CAGR
+49.36%
Free Cash Flow Yield
-13.14%
Beta (5Y)
1.34
Price Chart
Valuation
Market Cap$272M
P/S10.39
P/B1.62
Profitability
Gross Profit (TTM)$1.01M
EBITDA-$55M
EPS-$0.51
Financial Health
Free Cash Flow Yield-13.14%
Growth & Risk
FCF 5Y CAGR+49.36%
Beta (5Y)1.34
Sharpe Ratio0.52